Problems We Solve

The classic drug development paradigm is expensive (>$1.1B), takes a long time (8+ years), and doesn’t emphasize continuous, real-world outcome data to further refine research and development for additional patient populations.

The one-size-fits-all approach to drug and diagnostic development no longer fits into a highly competitive healthcare framework that demands more precise therapeutic solutions.